We address a significant unmet medical need by developing a new class of antibacterial agents that target antimicrobial resistance.
This is done either by a direct antimicrobial effect or by potentiating existing antibiotics. The compounds are new small molecule chemical entities from a well-developed chemical platform with excellent synthetic availability and desirable drug properties.
New class of antibacterial agents to combat antibiotic resistance
New mode of action
Target large and growing markets
High unmet medical need
ABOUT QURETECH BIO
QureTech Bio’s vision is to develop first-line drugs to combat infectious diseases and the occurrence of antibiotic resistance.
The company was founded in 2010 to commercialize world-leading research from groups based at Umeå University, Sweden, and Washington University, St Louis, USA. Since the foundation, several key persons have joined the company either as board members, researchers, or scientific advisors.
The company’s development programs are partly based on research funded by academic research grants. The company has also received soft funding from Umeå Biotech Incubator, the European Union Horizon 2020 program SME Instrument Phase 1, Swelife (a strategic innovation program funded by the Swedish innovation agency Vinnova), and by the ENABLE-2 program (funded by Vinnova).
Allow all cookies
Third Party Embeds
These cookies store information such as the number of visitors to the website, the number of unique visitors, which pages on the website have been visited, the source of the visit, etc. This data helps us to understand and analyze how well the website works. and where it needs to be improved.
From 25 May 2018, the General Data Protection Regulation (GDPR) applies as law in all EU member states.